Research Article

Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway

Figure 4

Anlotinib inhibits the migration of HSC-3 cells by suppressing the activation of the Akt pathway. (a) After HSC-3 cells were treated with different concentrations (0, 0.625, 1.25, and 2.5 μM/L) of anlotinib for 24 h, expression of the p-Akt and Akt proteins was detected by immunofluorescence. (b) Quantitative immunofluorescence results of the p-Akt and Akt proteins. (c) HSC-3 cells were treated with anlotinib for 24 hours, and total MMP-2 and MMP-9, phosphorylated and total Akt and β-actin were detected by western blotting. (d) Ratio change of the migration markers MMP-2, MMP-9, phosphorylated, and total Akt. The data are expressed as the of three repeats. compared with the control.
(a)
(b)
(c)
(d)